Paragangliomas 2

Common Name(s)

Paragangliomas 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Paragangliomas 2" for support, advocacy or research.

VHL Alliance

VHLA is dedicated to research, education, and support to improve awareness, diagnosis, treatment, and quality of life for those affected by VHL.

Last Updated: 5 Jan 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Paragangliomas 2" for support, advocacy or research.

VHL Alliance

VHLA is dedicated to research, education, and support to improve awareness, diagnosis, treatment, and quality of life for those affected by VHL.

http://www.vhl.org

Last Updated: 5 Jan 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Paragangliomas 2" returned 4 free, full-text research articles on human participants. First 3 results:

Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
 

Author(s): Do-Youn Oh, Tae-Won Kim, Young Suk Park, Sang Joon Shin, Seong Hoon Shin, Eun-Kee Song, Hyo Jin Lee, Kewn-Wook Lee, Yung-Jue Bang

Journal: Cancer. 2012 Dec;118(24):6162-70.

 

The current study was conducted to evaluate the efficacy and safety of everolimus in the treatment of patients with nonfunctioning neuroendocrine tumors (NETs) or pheochromocytomas/paragangliomas.

Last Updated: 4 Dec 2012

Go To URL
Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
 

Author(s): Kathryn S King, Clara C Chen, Dimitrios K Alexopoulos, Millie A Whatley, James C Reynolds, Nicholas Patronas, Alexander Ling, Karen T Adams, Paraskevi Xekouki, Howard Lando, Constantine A Stratakis, Karel Pacak

Journal: J. Clin. Endocrinol. Metab.. 2011 Sep;96(9):2779-85.

 

Accurate diagnosis of head and neck paragangliomas is often complicated by biochemical silence and lack of catecholamine-associated symptoms, making accurate anatomical and functional imaging techniques essential to the diagnostic process.

Last Updated: 7 Sep 2011

Go To URL
Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
 

Author(s): Alexandru Saveanu, Mihaela Muresan, Catherine De Micco, David Taieb, Anne-Laure Germanetti, Frederic Sebag, Jean-François Henry, Laurent Brunaud, Alain Enjalbert, Georges Weryha, Anne Barlier

Journal:

 

While somatostatin receptors (sst), through somatostatin-radiolabeled analogs, are used, mainly in second line, in the diagnosis and treatment of pheochromocytomas (PCC) and paragangliomas (PGL), the clinical significance of dopamine receptor subtype 2 (D₂) in PCC/PGL is unknown. ...

Last Updated: 22 Mar 2011

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Paragangliomas 2" returned 2 free, full-text review articles on human participants. First 3 results:

Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
 

Author(s): Carsten C Boedeker, Zoran Erlic, Stéphane Richard, Udo Kontny, Anne-Paule Gimenez-Roqueplo, Alberto Cascon, Mercedes Robledo, José M de Campos, Francien H van Nederveen, Ronald R de Krijger, Nelly Burnichon, José Gaal, Martin A Walter, Kirsten Reschke, Thorsten Wiech, Johannes Weber, Klaus Rückauer, Pierre Francois Plouin, Vincent Darrouzet, Sophie Giraud, Charis Eng, Hartmut P H Neumann

Journal: J. Clin. Endocrinol. Metab.. 2009 Jun;94(6):1938-44.

 

Head and neck paragangliomas (HNPs) occur as sporadic or familial entities, the latter mostly in association with germline mutations of the SDHB, SDHC, or SDHD (SDHx) genes. Heritable non-SDHx HNP might occur in von Hippel-Lindau disease (VHL, VHL gene), multiple endocrine neoplasia ...

Last Updated: 4 Jun 2009

Go To URL
The multidisciplinary management of paragangliomas of the head and neck, Part 2.
 

Author(s): Kenneth Hu, Mark S Persky

Journal: Oncology (Williston Park, N.Y.). 2003 Aug;17(8):1143-53; discussion 1154, 1158, 1161.

 

Paragangliomas most commonly occur in the carotid body, jugulotympanic area, and vagus nerve but have also been reported in other areas of the head and neck. These tumors are highly vascular and characteristically have early blood vessel and neural involvement, making their treatment ...

Last Updated: 11 Sep 2003

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.